Efficacy and safety of deep brain stimulation as an adjunct to pharmacotherapy for the treatment of Parkinson disease;La eficacia y la seguridad de la estimulación cerebral profunda adjunto a la farmacoterapia en el tratamiento de la enfermedad Parkinson

Annals of Pharmacotherapy

Volumn 46, Issue 2, 2012, Pages 248-254

  Sharma, Alok ^a   Szeto, Kaylene ^a   Desilets, Alicia R ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Deep brain stimulation; Parkinson disease

Indexed keywords

LEVODOPA;

BRAIN DEPTH STIMULATION; COGNITION; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DYSKINESIA; EMOTION; HUMAN; INTERPERSONAL COMMUNICATION; MEDLINE; MOTOR PERFORMANCE; NEUROSURGEON; PARKINSON DISEASE; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY OF LIFE; RANGE OF MOTION; REVIEW; SCORING SYSTEM; SOCIAL SUPPORT; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; DEEP BRAIN STIMULATION; HUMANS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84863409621     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q508     Document Type: Review

References (26)

1. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009;72:S1-136.
2. Lang AE, Lozano AM. Parkinson's disease. Part 2 of 2. N Engl J Med 1998;339:1130-43.
3. Chen JJ, Swope DM. Pharmacotherapy for Parkinson's disease. Pharmacotherapy 2007;27:161S-73S.
4. Lew M. Overview of Parkinson's disease. Pharmacotherapy 2007;27: 155S-60S.
5. Lang AE, Lozano AM. Parkinson's disease. Part 1 of 2. N Engl J Med 1998;339:1044-53.
6. Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010;9:581-91.
7. Poewe W. Treatments for Parkinson disease-past achievements and current clinical needs. Neurology 2009;72:S65-73.
8. Esselink RA, de Bie RM, de Haan RJ, et al. Long-term superiority of subthalamic nucleus stimulation over pallidotomy in Parkinson disease. Neurology 2009;73:151-3.
9. Koller WC, Pahwa R, Lyons KE, Albanese A. Surgical treatment of Parkinson's disease. J Neurol Sci 1999;167:1-10.
10. Benabid AL, Pollak P, Gross C, et al. Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease. Stereotact Funct Neurosurg 1994;62:76-84.
11. Hariz M. Deep brain stimulation versus best medical therapy for advanced Parkinson's disease. Lancet Neurol 2009;8:223-4.
12. Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 2011;68:165.
13. McClelland S 3rd. A cost analysis of intraoperative microelectrode recording during subthalamic stimulation for Parkinson's disease. Mov Disord 2011;26:1422-7.
14. Carpinella I, Crenna P, Marzegan A, et al. Effect of L-dopa and subthalamic nucleus stimulation on arm and leg swing during gait in Parkinson's disease. Conf Proc IEEE Eng Med Biol Soc 2007;2007:6665-8.
15. Schupbach WM, Maltete D, Houeto JL, et al. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology 2007;68:267-71.
16. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355: 896-908.
17. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301:63-73.
18. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord 2006;21:1200-7.
19. Peto V, Jenkinson C, Fitzpatrick R. Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire. Age Ageing 2001;30:299-302.
20. Moro E, Volkmann J, Konig IR, et al. Bilateral subthalamic stimulation in parkin and PINK1 parkinsonism. Neurology 2008;70:1186-91.
21. Schupbach M, Lohmann E, Anheim M, et al. Subthalamic nucleus stimulation is efficacious in patients with parkinsonism and LRRK2 mutations. Mov Disord 2007;22:119-22.
22. Lohmann E, Welter ML, Fraix V, et al. Are parkin patients particularly suited for deep-brain stimulation? Mov Disord 2008;23:740-3.
23. Fraix V, Houeto JL, Lagrange C, et al. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:443-9.
24. Castrioto A, Lozano AM, Poon YY, Lang AE, Fallis M, Moro E. Tenyear outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol 2011;68:1550-6.
25. Lidstone SC, Schulzer M, Dinelle K, et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 2010;67:857-65.
26. Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deepbrain stimulation for Parkinson's disease. N Engl J Med 2010;362:2077-91.